Sign inJoin waitlistJoin the waitlist

Maro Ohanian

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2012–2013
Medical Oncology
2009–2011
Internal Medicine
University of Texas Medical Branch Hospitals
2006–2009
Texas Coll of Osteopathic Med
2002–2006

Research

Ibrutinib and Venetoclax for First-Line Treatment of CLL
New England Journal of Medicine · 2019 · 426 citations
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
Nature Medicine · 2023 · 334 citations
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
The Lancet Haematology · 2020 · 280 citations

Hagop Kantarjian
65 papers
Tapan Kadia
58 papers
Elias Jabbour
57 papers
GB
Gautam Borthakur
52 papers
Guillermo Garcia-Manero
49 papers
Naval Daver
47 papers
Courtney DiNardo
46 papers
Naveen Pemmaraju
45 papers
Nicholas Short
38 papers
Marina Konopleva
37 papers
Yesid Alvarado
34 papers
Koichi Takahashi
33 papers

Clinical trials

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2031
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2018–2027
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2018–2027
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Principal investigator · Withdrawn · Phase 1, Phase 2
Bio-Path Holdings, Inc.
2017–2020